Olema Pharmaceuticals (OLMA) Corporate presentation summary

Strategic focus and pipeline advancement

• Aims to transform metastatic breast cancer treatment with novel therapies targeting ER+ / HER2- subtypes, a market exceeding $20B globally.

• Lead candidate palazestrant is being developed as both monotherapy and in combination with ribociclib, targeting first-line and second/third-line settings.

• OP-3136, a KAT6 inhibitor, is in Phase 1 trials for breast and other solid tumors, showing synergy with palazestrant in preclinical models.

• Well-capitalized with over $500M in cash, supporting clinical milestones through 2027.

Palazestrant clinical development and differentiation

• Palazestrant is a complete estrogen receptor antagonist (CERAN) and SERD, designed for optimal efficacy in both ESR1 mutant and wild-type tumors.

• Demonstrates strong efficacy and safety as monotherapy in 2/3L ER+ / HER2- MBC, with median PFS of 7.3 months in ESR1 mutant and 5.5 months in wild-type patients.

• In combination with ribociclib, palazestrant shows median PFS of 15.5 months in all patients and 12.2 months in those previously treated with CDK4/6i.

• Safety profile is favorable, with most adverse events being low grade and consistent with established therapies.

• FDA Fast Track designation for palazestrant in patients progressing after endocrine therapy plus CDK4/6 inhibitor.

Market opportunity and commercial planning

• ER+ / HER2- metastatic breast cancer represents a $20B+ global market, with palazestrant targeting $5B+ in 2/3L and $10B+ in 1L settings.

• U.S. commercial launch of palazestrant monotherapy in 2/3L MBC anticipated in 2027, with a targeted field force and manufacturing infrastructure in development.

• OP-3136 targets an additional $5B+ market, with initial clinical data expected in 2026.